Feb 14 (Reuters) - Theratechnologies Inc:
* Theratechnologies announces new data from the pivotal phase III trial of HIV monoclonal antibody and long-acting investigational antiretroviral Ibalizumab
* Theratechnologies - patients enrolled in phase III trial experienced significant decrease in viral load after receiving single loading dose of Ibalizumab 2,000 mg
* Says no notable trends in laboratory abnormalities were observed.
* Says safety results in this phase III trial are consistent with ones previously observed in phase IIB trial. Source text for Eikon: Further company coverage: